Cargando…
Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial
Background: Chromium picolinate could be effective in clomiphen citrate resistant PCOS patients. Objective: To compare the effects of chromium picolinate vs. metformin in clomiphen citrate resistant PCOS patients. Materials and Methods: The present randomized clinical trial was performed on 92 women...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research and Clinical Center for Infertility
2013
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941367/ https://www.ncbi.nlm.nih.gov/pubmed/24639797 |
_version_ | 1782305905332715520 |
---|---|
author | Amooee, Sedigheh Parsanezhad, Mohammad Ebrahim Ravanbod Shirazi, Maryam Alborzi, Saeed Samsami, Alamtaj |
author_facet | Amooee, Sedigheh Parsanezhad, Mohammad Ebrahim Ravanbod Shirazi, Maryam Alborzi, Saeed Samsami, Alamtaj |
author_sort | Amooee, Sedigheh |
collection | PubMed |
description | Background: Chromium picolinate could be effective in clomiphen citrate resistant PCOS patients. Objective: To compare the effects of chromium picolinate vs. metformin in clomiphen citrate resistant PCOS patients. Materials and Methods: The present randomized clinical trial was performed on 92 women with clomiphen citrate-resistant PCOS at the clinics which were affiliated to Shiraz University of Medical Sciences, Shiraz, Iran. The subjects were randomly assigned to two groups receiving either chromium picolinate (200µg daily) or metformin (1500mg daily) for 3 months. Anthropometric and hormonal profile were measured and compared both before and after the treatment. Ovulation and pregnancy rate was measured in the two study groups, as well. Results: Chromium picolinate significantly decreased fasting blood sugar (FBS) after 3 months of treatment (p=0.042). In the same way, the serum levels of fasting insulin had significantly decreased leading to an increase in insulin sensitivity as measured by QUICKI index (p=0.014). In comparison to the patients who received chromium picolinate, those who received metformin had significantly lower levels of testosterone (p=0.001) and free testosterone (p=0.001) after 3 months of treatment. Nevertheless, no significant difference was found between the two study groups regarding ovulation (p=0.417) and pregnancy rates (p=0.500). Conclusion: Chromium picolinate decreased FBS and insulin levels and, thus, increased insulin sensitivity in clomiphene citrate-resistance PCOS women. These effects were comparable with metformin; however, metformin treatment was associated with decreased hyperandrogenism. Overall, chromium picolinate was better tolerated compared to metformin; nonetheless, the two study groups were not significantly different regarding ovulation and pregnancy rates. Registration ID in IRCT: IRCT201203139281N1 |
format | Online Article Text |
id | pubmed-3941367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Research and Clinical Center for Infertility |
record_format | MEDLINE/PubMed |
spelling | pubmed-39413672014-03-17 Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial Amooee, Sedigheh Parsanezhad, Mohammad Ebrahim Ravanbod Shirazi, Maryam Alborzi, Saeed Samsami, Alamtaj Iran J Reprod Med Background: Chromium picolinate could be effective in clomiphen citrate resistant PCOS patients. Objective: To compare the effects of chromium picolinate vs. metformin in clomiphen citrate resistant PCOS patients. Materials and Methods: The present randomized clinical trial was performed on 92 women with clomiphen citrate-resistant PCOS at the clinics which were affiliated to Shiraz University of Medical Sciences, Shiraz, Iran. The subjects were randomly assigned to two groups receiving either chromium picolinate (200µg daily) or metformin (1500mg daily) for 3 months. Anthropometric and hormonal profile were measured and compared both before and after the treatment. Ovulation and pregnancy rate was measured in the two study groups, as well. Results: Chromium picolinate significantly decreased fasting blood sugar (FBS) after 3 months of treatment (p=0.042). In the same way, the serum levels of fasting insulin had significantly decreased leading to an increase in insulin sensitivity as measured by QUICKI index (p=0.014). In comparison to the patients who received chromium picolinate, those who received metformin had significantly lower levels of testosterone (p=0.001) and free testosterone (p=0.001) after 3 months of treatment. Nevertheless, no significant difference was found between the two study groups regarding ovulation (p=0.417) and pregnancy rates (p=0.500). Conclusion: Chromium picolinate decreased FBS and insulin levels and, thus, increased insulin sensitivity in clomiphene citrate-resistance PCOS women. These effects were comparable with metformin; however, metformin treatment was associated with decreased hyperandrogenism. Overall, chromium picolinate was better tolerated compared to metformin; nonetheless, the two study groups were not significantly different regarding ovulation and pregnancy rates. Registration ID in IRCT: IRCT201203139281N1 Research and Clinical Center for Infertility 2013-08 /pmc/articles/PMC3941367/ /pubmed/24639797 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Amooee, Sedigheh Parsanezhad, Mohammad Ebrahim Ravanbod Shirazi, Maryam Alborzi, Saeed Samsami, Alamtaj Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial |
title | Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial |
title_full | Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial |
title_fullStr | Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial |
title_full_unstemmed | Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial |
title_short | Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial |
title_sort | metformin versus chromium picolinate in clomiphene citrate-resistant patients with pcos: a double-blind randomized clinical trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941367/ https://www.ncbi.nlm.nih.gov/pubmed/24639797 |
work_keys_str_mv | AT amooeesedigheh metforminversuschromiumpicolinateinclomiphenecitrateresistantpatientswithpcosadoubleblindrandomizedclinicaltrial AT parsanezhadmohammadebrahim metforminversuschromiumpicolinateinclomiphenecitrateresistantpatientswithpcosadoubleblindrandomizedclinicaltrial AT ravanbodshirazimaryam metforminversuschromiumpicolinateinclomiphenecitrateresistantpatientswithpcosadoubleblindrandomizedclinicaltrial AT alborzisaeed metforminversuschromiumpicolinateinclomiphenecitrateresistantpatientswithpcosadoubleblindrandomizedclinicaltrial AT samsamialamtaj metforminversuschromiumpicolinateinclomiphenecitrateresistantpatientswithpcosadoubleblindrandomizedclinicaltrial |